EU seals second COVID-19 vaccine deal as deadline for WHO-led scheme looms
Reuters
Published Sep 18, 2020 10:46
Updated Sep 18, 2020 11:00
BRUSSELS (Reuters) - The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi (PA:SASY) and GSK (L:GSK) in its second such deal to secure supplies, as a deadline for signing up to the World Health Organization's vaccine purchase programme looms.
The deal will see the French and British drugmakers, which have teamed up to manufacture a recombinant protein-based vaccine they hope to get approved next year, provide the EU with up to 300 million doses, according to a tweet from European Health Commissioner Stella Kyriakides.
Friday's agreement confirms an announcement made on July 31 by the two companies and follows an earlier deal between the EU and AstraZeneca (L:AZN) for up to 400 million shots.
The latest deal comes on deadline day for members of the WHO to join its COVAX scheme, which aims to buy COVID-19 vaccines and ensure immunisations are then fairly and efficiently distributed.
In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. The vaccine doses themselves will be bought by EU countries.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.